Head-to-head · Cost-Efficiency Index
TideMedix vs Aquivia Health
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
TideMedix
Cost-first shoppers who want not recommended without calling to confirm the post-first-month price before signing up.
Visit TideMedixAquivia Health
Cost-first shoppers who want clinician-reviewed compounded GLP-1 with optional branded upgrade.
Visit Aquivia HealthThe verdict
TideMedix and Aquivia Health tie on the Cost-Efficiency Index at 62/100, so neither wins outright on the numbers. For most shoppers we'd start with TideMedix (ranked #214, a hair above #217) — Cost-first shoppers who want not recommended without calling to confirm the post-first-month price before signing up. But Aquivia Health is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs TideMedix.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | TideMedix | Aquivia Health |
|---|---|---|
| Cost-Efficiency Index | 62/100 | 62/100 |
| Semaglutide / mo | $99/mo (compounded) | $149/mo |
| Tirzepatide / mo | Not disclosed | $179/mo |
| Semaglutide / yr (modeled) | $1,188 | $1,788 |
| Tirzepatide / yr (modeled) | — | $2,148 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #214 | #217 |
TideMedix
62/100Where the value is
- Repeated, prominent LegitScript certification claims
- Low advertised entry price ($99) for the first month
- Standard FDA compounding disclaimer present, suggesting legitimate compounded-drug awareness
The tradeoffs
- Headline $99 price is explicitly first-month-only; the ongoing monthly cost is never disclosed on the site
- No named medical director anywhere in the accessible content
Aquivia Health
62/100Where the value is
- Clinical care provided by Open Loop Healthcare Partners, PC — a reused, verified MSO network
- Named leadership: Steven Bishop MD (CMO), Phillip Gray PharmD (Chief Pharmacist), Tom Foster (President)
- Itemized public pricing: compounded semaglutide $149/mo, tirzepatide $179/mo, Ozempic $1,299, Zepbound $1,399
The tradeoffs
- No public list of states served — you must complete intake to learn if your state qualifies
- No named 503A compounding pharmacy partner, limiting licensure verification
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.